MDR

ibalizumab HIV

Ibalizumab: First Long Acting HIV Treatment Available Now Via Expanded Access

Blogger / By

No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control their viral replication. Although …

Ibalizumab: First Long Acting HIV Treatment Available Now Via Expanded Access Read More »

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

Leave a Comment / Blogger, Uncategorized / By

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

Leave a Comment / Blogger, Uncategorized / By

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel (NelsonVergel@yahoo.com) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with …

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »